Menu Login / Registration Search

CLIA Chlamydia pneumoniae IgM

Chemiluminescence kit for the detection of IgM antibodies to Chlamydia pneumoniae in human serum or plasma

Catalog Number: CL-CPM100
Size: 100 tests
Regulatory status: CE IVD
Clinical topic: Infectious Diseases
Diagnostic panel: COVID-19
Respiratory Diseases
CLIA Chlamydia pneumoniae IgM
  • Detection of IgM antibodies to Chlamydia pneumoniae
  • Disease stage specification
  • Intended for human serum and plasma
  • The purified and inactivated antigen of C. pneumoniae used

Chlamydiae are gram-negative bacteria, obligate intracellular parasites. Among them, Chlamydia pneumoniae is the most widespread species in the human population and can cause respiratory tract infections, such as pneumonia. In recent years, the number of acute and chronic infections has increased. The Primary infection usually occurs between 5 and 18 years of age. The typical clinical symptoms include rhinitis, sinusitis, otitis media, pharyngitis, bronchitis, atypical pneumonia with non-productive cough and indistinctive auscultatory findings. In the past 20 years, researchers have linked a wide variety of diseases to C. pneumoniae infection.

Technical specifications

Technical data
Related Products

Technical data

Assay stability30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
Sample matrix Serum, Plasma
Sample volume10 µL
Measuring range5 - 100 U/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions

The kits are CE-IVD certified and intended for professional use.


References to CLIA Chlamydia pneumoniae IgM

  • Hammerschlag MR. Pneumonia due to Chlamydia pneumoniae in children: epidemiology, diagnosis, and treatment. Pediatr Pulmonol. 2003 Nov;36(5):384-90. doi: 10.1002/ppul.10326. PMID: 14520720.
    See more on PubMed
  • Lieberman D, Lieberman D. Atypical pathogen pneumonia. Curr Opin Pulm Med. 1997 Mar;3(2):111-5. doi: 10.1097/00063198-199703000-00005. PMID: 9193855.
    See more on PubMed
  • Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010 Jan 15;50(2):202-9. doi: 10.1086/648678. PMID: 20014950; PMCID: PMC7107844.
    See more on PubMed
  • Hammerschlag MR, Reznik T, Roblin PM, Ramirez J, Summersgill J, Bukofzer S. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. J Antimicrob Chemother. 2003 Apr;51(4):1025-8. doi: 10.1093/jac/dkg154. Epub 2003 Feb 25. PMID: 12654764.
    See more on PubMed
  • Peeling RW. Laboratory diagnosis of Chlamydia pneumoniae infections. Can J Infect Dis. 1995 Jul;6(4):198-203. doi: 10.1155/1995/696950. PMID: 22514397; PMCID: PMC3327923.
    See more on PubMed
  • Villegas E, Sorlózano A, Gutiérrez J. Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives. J Med Microbiol. 2010 Nov;59(Pt 11):1267-1274. doi: 10.1099/jmm.0.020362-0. Epub 2010 Aug 19. PMID: 20724512.
    See more on PubMed

Related Products


Safety information

Declaration of conformity

EC Certificate

Find documents for the lot

Do you want to learn more about products? We're here for you.

Please fill in
all fields
marked *